The Living Guidelines: Recommendations for Revascularization with PCI and CABG in Asymptomatic Patients Suggest Revisions to the CLASS IIb Guidelines

Any recommendations found on these pages are for education use only. WikiDoc is not a substitute for a licensed healthcare provider. Please see the disclaimers page for important information regarding limitations of the information found here. In suggesting edits to the guidelines, WikiDoc suggests that the following classification scheme be used. Read more about the classification scheme used by the ACC / AHA Guidelines Committee here.

Instructions on How to Edit the Guidelines:
 * Log in
 * Click on "Edit"
 * Type in changes to guidelines
 * Click "Save page" at the bottom of the page

Class IIb Guidelines

 * 1) Compared with CABG, PCI for patients with 2 or 3 vessel disease with significant proximal LAD coronary artery disease who have anatomy suitable for catheter based therapy and who have treated diabetes or abnormal left ventricular function. (Class IIb Level of Evidence: B)
 * 2) Use of PCI for patients with significant left main coronary artery disease who are not candidates for CABG. (Class IIb Level of Evidence: C)
 * 3) Percutaneous coronary intervention for patients with one or two vessel coronary artery disease without significant proximal LAD coronary artery disease who have survived sudden cardiac death or sustained ventricular tachycardia. (Class IIb Level of Evidence: C)
 * 4) Repeat CABG for patients with multiple saphenous vein graft stenosis, with high risk criteria on non invasive testing, especially when there is significant stenosis of a graft supplying the LAD. Percutaneous coronary intervention may be appropriate for focal saphenous vein graft lesions or multiple stenoses in poor candidates for re operative surgery. (Class IIb Level of Evidence: C)
 * 5) Percutaneous coronary intervention or CABG for patients with one or two vessel coronary artery disease without significant proximal LAD coronary artery disease but with a moderate area of viable myocardium and demonstrable ischemia on non invasive testing. (Class IIb Level of Evidence: C)